JTO Clinical and Research Reports最新文献

{"title":"Histologic Grade 3 in Stage 1A Lung Adenocarcinoma: Survival Risks Comparable to Stage 1B","authors":"Gyerim Park MD ,&nbsp;Youngkyu Moon MD, PhD ,&nbsp;Meejeong Kim MD, PhD ,&nbsp;Kyo Young Lee MD, PhD ,&nbsp;Yeoun Eun Sung MD, PhD","doi":"10.1016/j.jtocrr.2025.100846","DOIUrl":"10.1016/j.jtocrr.2025.100846","url":null,"abstract":"<div><h3>Introduction</h3><div>Early stage NSCLC presents a significant risk of recurrence despite surgical resection. The International Association for the Study of Lung Cancer–proposed histologic grading system identifies high-grade tumors (≥20% solid, micropapillary, or complex glandular patterns) as a potential prognostic tool. This study evaluates the prognostic significance of histologic grade 3 within stage IA non-mucinous adenocarcinoma and its comparability to stage IB.</div></div><div><h3>Methods</h3><div>We retrospectively analyzed 729 patients with stage I non-mucinous adenocarcinoma who underwent surgical resection (2010–2017). Tumors were graded per the International Association for the Study of Lung Cancer system. Kaplan-Meier survival curves and Cox proportional hazards models assessed overall survival (OS) and disease-free survival (DFS).</div></div><div><h3>Results</h3><div>Stage IA grade 3 tumors demonstrated significantly worse OS and DFS compared with grade 1 and 2 tumors (<em>p</em> &lt; 0.001). Survival outcomes for stage IA grade 3 tumors were comparable to stage IB (<em>p</em> = 0.677 for OS, <em>p</em> = 0.248 for DFS). Stage IA grade 3 tumors also demonstrated a trend toward worse survival than stage IB grades 1 and 2. Grade 3 tumors exhibited sufficient risk stratification power, comparable to the already well-established risk factor of pleural invasion. Tumors with any high-grade patterns (&gt;0%) had poorer survival than those without, but risks were less pronounced than the 20% cutoff.</div></div><div><h3>Conclusions</h3><div>Histologic grade 3 in stage IA identifies high-risk tumors comparable to stage IB, highlighting its potential for refining staging criteria and guiding adjuvant therapy. Validation studies are needed to confirm these findings.</div></div>","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":"7 3","pages":"Article 100846"},"PeriodicalIF":3.5,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147378170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Thymic Neuroendocrine Tumors: Evolving Insights and Innovative Approaches","authors":"Erica Pietroluongo MD, PhD ,&nbsp;Christine M. Bestvina MD ,&nbsp;Rachel Brattin ,&nbsp;Pietro De Placido MD, PhD ,&nbsp;Anna Di Lello MD ,&nbsp;Waqas Haque MD, MPH ,&nbsp;Alessandra Esposito PhD ,&nbsp;Roberto Bianco MD, PhD ,&nbsp;Noura Choudhury MD ,&nbsp;Marina Chiara Garassino MD","doi":"10.1016/j.jtocrr.2025.100935","DOIUrl":"10.1016/j.jtocrr.2025.100935","url":null,"abstract":"<div><h3>Introduction</h3><div>Thymic neuroendocrine tumors (TNENs) are exceptionally rare and a clinically heterogeneous malignancy, often diagnosed at an advanced stage and lacking standardized treatment algorithms. Due to the scarcity of dedicated evidence, most therapeutic strategies are extrapolated from other neuroendocrine neoplasms.</div></div><div><h3>Methods</h3><div>This narrative review provides an updated overview of current and emerging treatment approaches for TNENs, focusing on histology-driven strategies and the evolving role of targeted and radionuclide therapies. A comprehensive literature search was conducted through PubMed/MEDLINE and Embase from January 1, 2000, up to May 31, 2025, integrating retrospective series, real-world data, and ongoing clinical trials.</div></div><div><h3>Results</h3><div>Surgical resection remains the cornerstone of treatment whenever feasible. The benefit of adjuvant therapy in well-differentiated tumors is unclear, whereas thymic neuroendocrine carcinomas often require multimodal approaches, including platinum–etoposide chemotherapy and radiotherapy. Retrospective evidence suggests that even well-differentiated, high-grade tumors may respond to cytotoxic agents. Somatostatin analogues are widely used in indolent or peptide receptor-positive tumors, whereas everolimus and, more recently, cabozantinib represent options for progressive disease. Peptide receptor radionuclide therapy has demonstrated encouraging results in somatostatin receptor–positive tumors and is currently under further investigation in prospective trials involving thymic primaries. However, the 5-year overall survival rate varies significantly (approximately 28%–80%), underlining an urgent need for prospective, subtype-specific studies.</div></div><div><h3>Conclusions</h3><div>The management of TNENs requires a multidisciplinary and individualized approach based on histologic subtype, somatostatin receptor status, and disease aggressiveness. Despite promising therapeutic options, robust prospective data remain limited. The integration of TNENs into basket trials, the molecular refinement of prognostic subgroups (e.g., NET G3), and the conduct of dedicated multicenter prospective studies are urgently needed to define optimal treatment algorithms and improve clinical outcomes in these rare entities.</div></div>","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":"7 2","pages":"Article 100935"},"PeriodicalIF":3.5,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145980963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Landscape of CEACAM5 Expression by Immunohistochemistry in NSCLC","authors":"Ying-Han R. Hsu MD, FRCPC ,&nbsp;Amna Almutrafi MD ,&nbsp;Katrina Hueniken MSc ,&nbsp;Alhareth Azaizeh MD ,&nbsp;Likun Hou MD, PhD ,&nbsp;Quan Li PhD ,&nbsp;Mackenzie Bates BSc ,&nbsp;Nhu-An Pham PhD ,&nbsp;Ming-Sound Tsao MD, FRCPC","doi":"10.1016/j.jtocrr.2025.100943","DOIUrl":"10.1016/j.jtocrr.2025.100943","url":null,"abstract":"<div><h3>Introduction</h3><div>Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) is a target of antibody-drug conjugate therapy for NSCLC. High expression of CEACAM5 has been reported in approximately 25% of patients with lung adenocarcinoma. However, CEACAM5 expression has not been systematically examined in a real-world and large patient population with NSCLC. There are also limited data on the prognostic impact of CEACAM5 protein expression.</div></div><div><h3>Methods</h3><div>We assessed CEACAM5 protein expression by immunohistochemistry in two separate cohorts of patients with NSCLC to include both routine clinical biopsy and resection specimens, using the anti-CEACAM5 clone 769 antibody assay protocol and scoring scheme for the tusamitamab ravtansine clinical trials. Expression levels were categorized as high (≥50% tumor cells at ≥2+ intensity), moderate (1%–49% tumor cells at ≥2+ intensity), and negative (0/1+ intensity) and scored independently by three thoracic pathologists. Interrater reliability was determined by Kendall’s coefficient of concordance and Fleiss’ kappa. Association with PD-L1 and driver mutation was calculated by Fisher exact or chi-square test. Correlation with recurrence-free survival and overall survival was determined by log-rank tests.</div></div><div><h3>Results</h3><div>The interrater reliability of CEACAM5 assessment was moderate among three pathologists. The overall prevalence of high CEACAM5 expression was 18%. CEACAM5 expression did not significantly correlate with tumor stage, PD-L1 expression, tumor mutation burden, and <em>EGFR</em> or <em>KRAS</em> mutations. There was no prognostic effect of CEACAM5 expression on recurrence-free survival or overall survival.</div></div><div><h3>Conclusions</h3><div>Our data revealed that 18% of routinely diagnosed clinical NSCLC samples had high CEACAM5 expression by immunohistochemistry, and its expression was not associated with oncogenic driver mutations or patient prognosis in a predominantly early stage NSCLC cohort.</div></div>","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":"7 2","pages":"Article 100943"},"PeriodicalIF":3.5,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145980964","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Curative-Intent Multimodality Treatment for NSCLC: Will Global Healthcare Systems Rise to the Challenge? A Perspective From the United Kingdom","authors":"Matthew Evison MD, MRCP ,&nbsp;Shobhit Baijal MBBS, BSc (Hons) ,&nbsp;Mayuri Basnet MBBS, FRCPath ,&nbsp;Tim Batchelor MSc, FRCS (CTh) ,&nbsp;Karen Clayton MSc ACP ,&nbsp;Lorraine Dallas BA ,&nbsp;Alastair Greystoke PhD ,&nbsp;Adam Januszewski PhD ,&nbsp;Neal Navani PhD ,&nbsp;Riyaz Shah PhD ,&nbsp;Annabel Sharkey PhD, FRCS (CTh) ,&nbsp;Jyotika Singh MBA","doi":"10.1016/j.jtocrr.2025.100923","DOIUrl":"10.1016/j.jtocrr.2025.100923","url":null,"abstract":"","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":"7 2","pages":"Article 100923"},"PeriodicalIF":3.5,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146024149","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment Patterns, Prognostic Factors and Survival for ALK-Positive Advanced NSCLC In Australia: Results From the Australasian Thoracic Cancers Longitudinal Cohort Study and Biobank (AURORA)","authors":"Grace Chazan FRACP ,&nbsp;Marliese Alexander PhD ,&nbsp;Fanny Franchini PhD ,&nbsp;Maarten IJzerman PhD ,&nbsp;Roma Shah MPH ,&nbsp;Ani John PhD ,&nbsp;Tim Spelman PhD ,&nbsp;Malinda Itchins PhD ,&nbsp;Nick Pavlakis PhD ,&nbsp;Adnan Nagrial PhD ,&nbsp;Lydia Warburton FRACP ,&nbsp;Samantha Bowyer FRACP ,&nbsp;Steven Kao PhD ,&nbsp;Sagun Parakh PhD ,&nbsp;Benjamin J. Solomon PhD","doi":"10.1016/j.jtocrr.2025.100924","DOIUrl":"10.1016/j.jtocrr.2025.100924","url":null,"abstract":"<div><h3>Introduction</h3><div>Advanced lung cancer has historically been associated with poor survival. However, with the advent of targeted therapies, outcomes are improving. Among patients with <em>ALK-</em>rearranged advanced NSCLC (ALK+ aNSCLC), real-world data on treatment patterns, prognostic factors, and survival in the era of contemporary therapy remain limited.</div></div><div><h3>Methods</h3><div>We conducted a retrospective observational cohort study using deidentified patient, disease, and outcomes data from the AUstralasian thoRacic cancers lOngitudinal cohoRt study and biobAnk (AURORA; ACTRN12625000038493). Eligible patients were diagnosed with ALK+ aNSCLC between 2006 and 2025.</div></div><div><h3>Results</h3><div>Of the 4776 patients with thoracic malignancies enrolled across eight sites (as of April 2025), 218 met the inclusion criteria—the largest reported Australian cohort of ALK+ aNSCLC. All patients were treated in academic centers. The median age was 55 years; 54% were female, 66% were never-smokers, and 41% had participated in a clinical trial. The median overall survival was 90.8 months (95% CI: 69.8–not reached). Nearly all patients (99%) received an ALK inhibitor; 83% in the first-line setting. Treatment sequences evolved over time. Most (68%) received at least two lines of therapy; 21% received 4 or more lines. Smoking status, age, and Eastern Cooperative Oncology Group Performance Status were prognostically associated with survival.</div></div><div><h3>Conclusion</h3><div>This study highlights the remarkable survival achievable in the real-world setting for some patients with ALK+ aNSCLC, compared with historical cohorts. Several clinical factors associated with survival were identified. Larger studies are needed to investigate how treatment sequences may be optimized to further improve survival outcomes.</div></div>","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":"7 2","pages":"Article 100924"},"PeriodicalIF":3.5,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146024079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient-Reported Symptoms and Quality of Life With Sacituzumab Govitecan Versus Docetaxel in Metastatic NSCLC: The Phase 3, Randomized EVOKE-01 Trial","authors":"Niels Reinmuth MD ,&nbsp;Sébastien Couraud MD, PhD ,&nbsp;Luis Paz-Ares MD, PhD ,&nbsp;Marina Chiara Garassino MD ,&nbsp;Shobhit Baijal MBBS, BSc ,&nbsp;Davey Daniel MD ,&nbsp;Pilar Garrido MD, PhD ,&nbsp;Terufumi Kato MD ,&nbsp;Ivor Percent MD ,&nbsp;Achim Rittmeyer MD ,&nbsp;Hector Soto Parra MD ,&nbsp;Sabeen Mekan MD ,&nbsp;Mira Patel PhD ,&nbsp;Matthew Radford PhD ,&nbsp;Eric Zhang PhD ,&nbsp;Christopher G. Pelligra MS ,&nbsp;Shien Guo PhD ,&nbsp;Enriqueta Felip MD, PhD","doi":"10.1016/j.jtocrr.2025.100929","DOIUrl":"10.1016/j.jtocrr.2025.100929","url":null,"abstract":"<div><h3>Introduction</h3><div>In the phase 3 EVOKE-01 trial (NCT05089734), sacituzumab govitecan (SG) exhibited a numerical improvement in overall survival and tolerability compared with docetaxel in patients with metastatic NSCLC previously treated with platinum-based chemotherapy and programmed cell death protein (ligand) 1 inhibitors, although results were not statistically significant. This analysis evaluated health-related quality of life (HRQoL) data from EVOKE-01.</div></div><div><h3>Methods</h3><div>Patients (N = 603) were randomized 1:1 to SG (n = 299) or docetaxel (n = 304) in 21-day cycles. HRQoL was assessed by the NSCLC Symptom Assessment Questionnaire (NSCLC-SAQ), European Organization for Research and Treatment of Cancer Quality of Life questionnaire–Core 30 (QLQ-C30), and EuroQol 5 Dimension 3-level questionnaire. Least square mean changes from baseline at week 25, time to first meaningful deterioration or death, and time to confirmed deterioration were analyzed.</div></div><div><h3>Results</h3><div>SG exhibited significantly and meaningfully better effects than docetaxel on NSCLC-SAQ shortness of breath (SoB), fatigue, total score, and on QLQ-C30 role functioning, fatigue, and dyspnea. Time to first meaningful deterioration or death favored SG over docetaxel for NSCLC-SAQ SoB (hazard ratio [95% confidence interval ]: 0.75 [0.61–0.91]), fatigue (0.70 [0.57–0.86]), and total score (0.80 [0.66–0.97]); QLQ-C30 fatigue (0.80 [0.66–0.96]) and dyspnea (0.74 [0.60–0.90]); and EuroQol visual analog scale (0.79 [0.65–0.96]). The time to confirmed deterioration favored SG over docetaxel for NSCLC-SAQ SoB (0.59 [0.44–0.77]) and fatigue (0.70 [0.52–0.95]), and QLQ-C30 fatigue (0.75 [0.59–0.95]).</div></div><div><h3>Conclusions</h3><div>These exploratory results suggest that SG may benefit HRQoL over docetaxel, supporting SG as an active therapeutic agent for metastatic NSCLC post platinum-based and programmed cell death protein (ligand) 1 inhibitor therapy.</div></div>","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":"7 2","pages":"Article 100929"},"PeriodicalIF":3.5,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145980962","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biomarker Testing and Patterns of Treatment in Patients with NSCLC: An International Association for The Study of Lung Cancer Analysis of American Society of Clinical Oncology CancerLinQ Discovery Data","authors":"Madhusmita Behera PhD ,&nbsp;Gregory Joseph MS ,&nbsp;Manali Rupji MS ,&nbsp;Zhonglu Huang MS ,&nbsp;Becky Bunn MS ,&nbsp;Murry W. Wynes PhD ,&nbsp;Jeffrey Switchenko PhD ,&nbsp;Giorgio V. Scagliotti MD ,&nbsp;Ming S. Tsao MD ,&nbsp;Chandra P. Belani MD ,&nbsp;Lecia V. Sequist MD ,&nbsp;Suresh S. Ramalingam MD","doi":"10.1016/j.jtocrr.2025.100816","DOIUrl":"10.1016/j.jtocrr.2025.100816","url":null,"abstract":"<div><h3>Introduction</h3><div>Precision medicine has resulted in improved outcomes for non small cell lung cancer (NSCLC), whereas biomarker testing is considered critical for guiding treatment decisions for advanced-stage NSCLC, and adoption of testing in routine practice is variable. We studied the utilization of biomarker testing in advanced NSCLC.</div></div><div><h3>Methods</h3><div>The American Society of Clinical Oncology (ASCO) CancerLinQ Discovery data set was queried to identify patients diagnosed with lung cancer between 2010 and 2018. Data on demographics, tumor stage, histology, and treatments were extracted, and receipt of biomarker testing was investigated as the primary outcome. Univariate association of each clinicopathological variable with the biomarker testing outcome was performed using a chi-square test for categorical variables and an analysis of variance test for numerical variables. A multivariable logistic regression analysis with backward selection at an alpha of 0.05 was reported. All analyses were conducted using SAS 9.4.</div></div><div><h3>Results</h3><div>A total of 37,925 patients with stage IV NSCLC were analyzed. The patients had a median age of 65 years; meanwhile, 51% of the participants were male individuals, 68% were white, and 33.5% had adenocarcinoma. Approximately 22% of all patients with NSCLC had biomarker testing results. Among the patients with adenocarcinoma, 49% had biomarker testing results available. In the stage IV group, 47% were treated with chemotherapy, 16% with immunotherapy, and 3.5% with targeted therapy. On multivariable analysis, female patients were more likely to have molecular testing compared with male patients (OR = 1.29, 95% confidence interval [CI]: 1.21–1.36, <em>p</em> &lt; 0.001). Compared with white patients, black patients were less likely to have biomarker testing (OR = 0.89, 95% CI: 0.81–0.97, <em>p</em> = 0.009), and Asians were more likely to undergo testing (OR = 2.21, 95% CI: 1.78–2.73, <em>p</em> &lt; 0.001). Hispanic patients were more likely to undergo biomarker testing than non-Hispanic (OR = 1.23, 95% CI: 1.01–1.50, <em>p</em> = 0.03). In addition, treatment with immunotherapy (OR = 1.86, 95% CI: 1.72–2.02, <em>p</em> &lt; 0.001) and targeted therapy (OR = 2.52, 95% CI: 2.21–2.88, <em>p</em> &lt; 0.001) were associated with a significantly higher likelihood of having biomarker testing. These results were also confirmed in a subgroup analysis of patients with adenocarcinoma.</div></div><div><h3>Conclusion</h3><div>In this analysis of a United States–based real-world data set of patients with stage IV NSCLC, the Asian race and female sex were associated with a higher likelihood of having biomarker testing performed. The overall percentage of patients undergoing testing remained suboptimal.</div></div>","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":"7 2","pages":"Article 100816"},"PeriodicalIF":3.5,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145929321","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"First Report of Response to Tarlatamab in a Patient With Histologic-Transformed SCLC From ALK-Rearranged NSCLC: Case Report","authors":"Kaiwen Wang PharmD ,&nbsp;Ceylan Altintas Taslic MD ,&nbsp;Patricia de Groot MD ,&nbsp;Mitchell A. Parma MD ,&nbsp;Alvaro Guimaraes Paula MD ,&nbsp;Melody Caranto MSN ,&nbsp;Komal Shah MD ,&nbsp;Mukulika Bose PhD ,&nbsp;Cole Ruoff BS ,&nbsp;Loukia G. Karacosta PhD ,&nbsp;Lauren A. Byers MD ,&nbsp;Carl M. Gay MD, PhD ,&nbsp;Jianjun Zhang MD, PhD ,&nbsp;John V. Heymach MD, PhD ,&nbsp;Bingnan Zhang MD, MBA","doi":"10.1016/j.jtocrr.2025.100941","DOIUrl":"10.1016/j.jtocrr.2025.100941","url":null,"abstract":"<div><div>Small cell transformation has been described as a resistance mechanism to targeted therapy treated in patients with <em>EGFR</em>-mutated NSCLC and less often reported with those with other actionable oncogenic alterations, including <em>ALK</em>-rearranged NSCLC. Given lack of standard-of-care treatments for patients with actionable oncogenic alteration NSCLC transformed to SCLC, this remains a challenge and unmet need for treating these patients.</div><div>Here, we present a case of a patient with <em>ALK</em>-rearranged NSCLC with transformation to SCLC, who has progressed on several lines of therapies and successfully treated with tarlatamab to elicit and maintain clinical benefit, including intracranial response.</div></div>","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":"7 2","pages":"Article 100941"},"PeriodicalIF":3.5,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145981051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pathologic Responses to Stereotactic Ablative Radiotherapy in Combination With Nivolumab for Early Stage NSCLC: A Phase 2 Study","authors":"Gustavo Schvartsman MD, PhD ,&nbsp;Yasmin M. Amirato MD ,&nbsp;Frederico Monfardini MSc ,&nbsp;Gustavo Prado dos Santos BSc ,&nbsp;Diogo B.D. Gomes MD ,&nbsp;Ludmila de O. M. Koch MD ,&nbsp;Benoit J. Bibas MD, PhD ,&nbsp;Oswaldo Gomes Jr. MD ,&nbsp;Paulo V. Campregher MD, PhD ,&nbsp;Patrícia Severino PhD ,&nbsp;Luciana C. Marti PhD ,&nbsp;Vitor R. Paes MD ,&nbsp;Laura Leaden PhD ,&nbsp;Rodrigo C. Chate MD ,&nbsp;Jose M. Ribas MD, PhD ,&nbsp;Victor.A.R. Sousa MD ,&nbsp;Patrícia Taranto MD ,&nbsp;Fernando Moura MD, PhD ,&nbsp;Ricardo M. Terra MD, PhD ,&nbsp;Ana Carolina Pires de Rezende MD ,&nbsp;Marcos N. Samano MD, PhD","doi":"10.1016/j.jtocrr.2025.100940","DOIUrl":"10.1016/j.jtocrr.2025.100940","url":null,"abstract":"<div><h3>Introduction</h3><div>Stereotactic ablative radiotherapy (SABR) is routinely used in patients with early stage NSCLC who are not candidates for surgery. Despite excellent local tumor control, it is associated with a high rate of regional and distant recurrences. Combining stereotactic radiotherapy with PD-1 inhibitors has demonstrated encouraging results for patients with curative intent, but how it affects the tumor microenvironment and pathologic response remains unclear.</div></div><div><h3>Methods</h3><div>We designed a phase II, open-label, single-arm study aimed to evaluate the efficacy and safety of neoadjuvant nivolumab combined with SABR in patients with NSCLC measuring up to 4 cm, without positive lymph nodes. Patients were required to be eligible for surgery, with adequate pulmonary and cardiovascular function. Nivolumab was administered at 360 mg every 21 days for three doses, combined with SABR, which was initiated concomitantly with the first cycle. Patients subsequently underwent surgical resection 10 weeks after the last dose of radiation. The primary end point was the pathologic complete response (pCR) rate at surgery. Secondary end points included major pathologic response (MPR) rate, safety, event-free survival, and overall survival at 12 months and a comprehensive biomarker analysis.</div></div><div><h3>Results</h3><div>A total of 25 patients were enrolled between November 2019 and February 2022. The mean age was 68 years, and 68% were female. The mean tumor size at baseline was 2.47 cm. A total of 24 patients fully completed the experimental therapy and proceeded with surgery. The primary end point of pCR was achieved by 19 of 24 patients (79.2%; 95% confidence interval: 57%–92%, <em>p</em> value 0.0875, in the per-protocol analysis). MPR was observed in 20 cases (83.3%; 95% confidence interval: 61.8%–94%). Four patients have not achieved an MPR, with one of them presenting with 100% residual viable tumor. No patient relapsed to date, with 12-month event-free survival and overall survival of 84%, with median not reached for both. One patient died from alcoholic hepatitis, unrelated to the treatment, and did not undergo resection. Two patients died from surgical complications.</div></div><div><h3>Conclusions</h3><div>The neoadjuvant combination of three doses of nivolumab and SABR produced a high pCR rate in stage I NSCLC. Further research is warranted to evaluate this treatment modality in patients with medically inoperable NSCLC and whether surgery could be safely omitted for patients who are candidates for resection.</div></div>","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":"7 2","pages":"Article 100940"},"PeriodicalIF":3.5,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146078905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"FDG-PET/CT SUVmax Predicts Recurrence Risk of Resected Pleuropulmonary Solitary Fibrous Tumors","authors":"Matthew Aizpuru MD ,&nbsp;Jennifer M. Boland MD ,&nbsp;Brendan W. Lunn MD ,&nbsp;Sahar A. Saddoughi MD, PhD ,&nbsp;K. Robert Shen MD ,&nbsp;Stephen D. Cassivi MD ,&nbsp;Dennis A. Wigle MD ,&nbsp;Janani S. Reisenauer MD ,&nbsp;Luis F. Tapias MD","doi":"10.1016/j.jtocrr.2025.100942","DOIUrl":"10.1016/j.jtocrr.2025.100942","url":null,"abstract":"<div><h3>Objectives</h3><div>Risk stratification of pleuropulmonary solitary fibrous tumors (SFTs) is based on post-resection histopathologic scoring systems. We queried whether preoperative 18-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) maximum standardized uptake values (SUVmax) had prognostic value for recurrence or metastasis.</div></div><div><h3>Methods</h3><div>Retrospective review of patients who underwent FDG-PET/CT before resection of SFT between January 2002 and June 2023. Independent review of slides by a pulmonary pathologist and radiologist review of FDG-PET/CT were performed. Statistical analyses included nonparametric tests for correlations, receiver-operating characteristic (ROC) curves, and Kaplan-Meier analysis.</div></div><div><h3>Results</h3><div>There were 34 patients with a preoperative FDG-PET/CT before SFT resection. Median tumor SUVmax was 2.3 (range: 0.9–38.7). Recurrence occurred in five patients (14.7%) (three local, two metastatic). Tumor SUVmax was associated with tumor size (<em>p</em> &lt; 0.001), parietal pleural origin (<em>p</em> = 0.027), hypercellularity (<em>p</em> = 0.049), mitoses (<em>p</em> &lt; 0.001), and Ki67 (<em>p</em> = 0.015). SUVmax correlated with the modified Demicco score (<em>p</em> &lt; 0.001) and Tapias score (<em>p</em> &lt; 0.001). Prediction of recurrence was excellent with SUVmax (area under ROC curve [AUC] = 0.872, <em>p</em> &lt; 0.001), Tapias score (AUC = 0.914, <em>p</em> &lt; 0.001), and modified Demicco score (AUC = 0.821, <em>p</em> &lt; 0.001). Time-dependent ROC analysis identified SUVmax more than or equal to 2.4 as high risk for recurrence. Recurrence-free survival at 1, 3, 5, and 10 years was 92.9%, 83.6%, 69.6%, and 46.4%, respectively, in patients with SUVmax more than or equal to 2.4, but it was 100% at all time points with SUVmax less than 2.4 (<em>p</em> = 0.002). SUVmax was not associated with overall survival in this small cohort.</div></div><div><h3>Conclusions</h3><div>Tumor metabolic activity on FDG-PET/CT is predictive of SFT recurrence. Preoperative SUVmax correlates with known histopathologic high-risk features and validated risk scores. Preoperative FDG-PET/CT should be performed before SFT resection to assist in prognostication.</div></div>","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":"7 2","pages":"Article 100942"},"PeriodicalIF":3.5,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145980965","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}